SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Daniel Levin, Samira Bell, Reijo Sund, Sirpa A. Hartikainen, Jaakko Tuomilehto, Eero Pukkala, Ilmo Keskimäki, Ellena Badrick, Andrew G. Renehan, Iain E. Buchan, Samantha L. Bowker, Jasjeet K. Minhas-Sandhu, Zafar Zafari, Carlo Marra, Jeffrey A. Johnson, Bruno H. Stricker, Andrè G. Uitterlinden, Albert Hofman, Rikje Ruiter, Catherine E. de Keyser, Thomas M. MacDonald, Sarah H. Wild, Paul M. McKeigue, Helen M. Colhoun, Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis, Diabetologia, 2015, 58, 3, 493

    CrossRef

  2. 2
    Shashank R Joshi, Saroglitazar for the treatment of dyslipidemia in diabetic patients, Expert Opinion on Pharmacotherapy, 2015, 16, 4, 597

    CrossRef

  3. 3
    Yuval Ramot, Arianna Mastrofrancesco, Emanuela Camera, Pierre Desreumaux, Ralf Paus, Mauro Picardo, The role of PPARγ-mediated signalling in skin biology and pathology: new targets and opportunities for clinical dermatology, Experimental Dermatology, 2015, 24, 4
  4. 4
    Anna R Carta, Tanya Simuni, Thiazolidinediones under preclinical and early clinical development for the treatment of Parkinson’s disease, Expert Opinion on Investigational Drugs, 2015, 24, 2, 219

    CrossRef

  5. 5
    Mohd Ashraf Ganie, Semanti Chakraborty, Hammadur Rehman, Treatment of polycystic ovary syndrome: recent trial results, Clinical Investigation, 2015, 5, 3, 337

    CrossRef

  6. 6
    Ganesh R. Kokil, Rakesh N. Veedu, Grant A. Ramm, Johannes B. Prins, Harendra S. Parekh, Type 2 Diabetes Mellitus: Limitations of Conventional Therapies and Intervention with Nucleic Acid-Based Therapeutics, Chemical Reviews, 2015, 150428100744000

    CrossRef

  7. 7
    Chin-Hsiao Tseng, A Review on Thiazolidinediones and Bladder Cancer in Human Studies, Journal of Environmental Science and Health, Part C, 2014, 32, 1, 1

    CrossRef

  8. 8
    Rury R Holman, Harald Sourij, Robert M Califf, Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes, The Lancet, 2014, 383, 9933, 2008

    CrossRef

  9. 9
    So Jin Shin, Jin Young Kim, Sun Young Kwon, Kyo-Cheol Mun, Chi Heum Cho, Eunyoung Ha, Ciglitazone enhances ovarian cancer cell death via inhibition of glucose transporter-1, European Journal of Pharmacology, 2014, 743, 17

    CrossRef

  10. 10
    Balasubramanian T. Srinivasan, Melanie Davies, Glycaemic management of type 2 diabetes, Medicine, 2014, 42, 12, 711

    CrossRef

  11. 11
    Fabian Linden, Gabriele Domschke, Christian Erbel, Mohammadreza Akhavanpoor, Hugo A. Katus, Christian A. Gleissner, Inflammatory therapeutic targets in coronary atherosclerosis—from molecular biology to clinical application, Frontiers in Physiology, 2014, 5,

    CrossRef

  12. 12
    Edith Morales, Reiko Sakurai, Sumair Husain, Dave Paek, Ming Gong, Basil Ibe, Yishi Li, Maleha Husain, John S. Torday, Virender K. Rehan, Nebulized PPARγ agonists: a novel approach to augment neonatal lung maturation and injury repair in rats, Pediatric Research, 2014, 75, 5, 631

    CrossRef

  13. 13
    K.-D. Lin, M.-Y. Lee, C.-C. Feng, B. K. Chen, M.-L. Yu, S.-J. Shin, Residual effect of reductions in red blood cell count and haematocrit and haemoglobin levels after 10-month withdrawal of pioglitazone in patients with Type 2 diabetes, Diabetic Medicine, 2014, 31, 11
  14. 14
    Sang-Man Jin, Sun Ok Song, Chang Hee Jung, Jin-Sun Chang, Sunghwan Suh, Seung Min Kang, Inkyung Jung, Cheol-Young Park, Jae Hyeon Kim, Jae Hyoung Cho, Byung-Wan Lee, Risk of Bladder Cancer among Patients with Diabetes Treated with a 15 mg Pioglitazone Dose in Korea: A Multi-Center Retrospective Cohort Study, Journal of Korean Medical Science, 2014, 29, 2, 238

    CrossRef

  15. 15
    A. Sahebkar, G. F. Watts, Role of selective peroxisome proliferator-activated receptor modulators in managing cardiometabolic disease: tale of a roller-coaster, Diabetes, Obesity and Metabolism, 2014, 16, 9
  16. 16
    Michael R. Gionfriddo, Oscar L. Morey-Vargas, Juan P. Brito, Aaron L. Leppin, M. Hassan Murad, Victor M. Montori, Systematic Reviews to Ascertain the Safety of Diabetes Medications, Current Diabetes Reports, 2014, 14, 4

    CrossRef

  17. 17
    Dilan Athauda, Thomas Foltynie, The ongoing pursuit of neuroprotective therapies in Parkinson disease, Nature Reviews Neurology, 2014, 11, 1, 25

    CrossRef

  18. 18
    Richard M. Turner, Chun S. Kwok, Chen Chen-Turner, Chinedu A. Maduakor, Sonal Singh, Yoon K. Loke, Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta-analysis, British Journal of Clinical Pharmacology, 2014, 78, 2
  19. 19
    Raymond E. Soccio, Eric R. Chen, Mitchell A. Lazar, Thiazolidinediones and the Promise of Insulin Sensitization in Type 2 Diabetes, Cell Metabolism, 2014, 20, 4, 573

    CrossRef

  20. 20
    L. Sciacca, R. Vigneri, A. Tumminia, F. Frasca, S. Squatrito, L. Frittitta, P. Vigneri, Clinical and molecular mechanisms favoring cancer initiation and progression in diabetic patients, Nutrition, Metabolism and Cardiovascular Diseases, 2013, 23, 9, 808

    CrossRef

  21. 21
    Tiange Wang, Guang Ning, Zachary Bloomgarden, Diabetes and cancer relationships (糖尿病与肿瘤的关联性), Journal of Diabetes, 2013, 5, 4
  22. 22
    Ji Weon Lee, Soon Jun Hong, Han Saem Jeong, Hyung Joon Joo, Jae Hyoung Park, Chul-Min Ahn, Cheol Woong Yu, Do-Sun Lim, Effects of a PPAR-γ (Peroxisome Proliferator-Activated Receptor-gamma) Activator on Flow-Mediated Brachial Artery Dilation and Circulating Level of microRNA-21 in Hypertensive Type 2 Diabetic Patients, Journal of the Korean Society of Hypertension, 2013, 19, 4, 99

    CrossRef

  23. 23
    Sang-Uk Kang, GPR119 agonists: a promising approach for T2DM treatment? A SWOT analysis of GPR119, Drug Discovery Today, 2013, 18, 23-24, 1309

    CrossRef

  24. 24
    Nobuhiro Tahara, Sho-ichi Yamagishi, Minori Mizoguchi, Atsuko Tahara, Tsutomu Imaizumi, Pioglitazone Decreases Asymmetric Dimethylarginine Levels in Patients with Impaired Glucose Tolerance or Type 2 Diabetes, Rejuvenation Research, 2013, 16, 5, 344

    CrossRef

  25. 25
    Hannah Seok, Bong Soo Cha, Refocusing Peroxisome Proliferator Activated Receptor-α: A New Insight for Therapeutic Roles in Diabetes, Diabetes & Metabolism Journal, 2013, 37, 5, 326

    CrossRef

  26. 26
    Jean-Luc Faillie, Pierre Petit, Jean-Louis Montastruc, Dominique Hillaire-Buys, Scientific Evidence and Controversies About Pioglitazone and Bladder Cancer: Which Lessons Can Be Drawn?, Drug Safety, 2013, 36, 9, 693

    CrossRef